Gengsheng Chen

Gengsheng Chen

Auto-generated profile, based on publicly available information

Gengsheng Chen

Department of Radiology, Washington University School of Medicine, Saint Louis, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 February 2024 in Neurology
Verified
Journal Article
Closed access
QWQing Wang
Qing Wang
SSSuzanne E. Schindler
Suzanne E. Schindler
GCGengsheng Chen
Gengsheng Chen
NMNicole S. Mckay
Nicole S. Mckay
AMAustin McCullough
Austin McCullough
TBTammie Benzinger
Tammie Benzinger
Alzheimer disease (AD) is primarily associated with accumulations of amyloid plaques and tau tangles in gray matter, however, it is now acknowledged that neuroinflammation, particularly in white matter (WM), significantly contributes to the development and progression of AD. This study aims to investigate WM neuroinflammation in the continuum of AD and its association with AD pathologies and cognition using diffusion-based neuroinflammation imaging (NII). This is a cross-sectional, single-center, retrospective evaluation conducted on an observational study of 310 older research participants who were enrolled in the Knight Alzheimer's Disease Research Center cohort. Hindered water ratio (HR), an index of WM neuroinflammation, was quantified by a noninvasive diffusion MRI method, NII. The alterations of NII-HR were investigated at different AD stages, classified based on CSF concentrations of β-amyloid (Aβ) 42/Aβ40 for amyloid and phosphorylated tau181 (p-tau181) for tau. On the voxel and regional levels, the relationship between NII-HR and CSF markers of amyloid, tau, and neuroinflammation were examined, as well as cognition. This cross-sectional study included 310 participants (mean age 67.1 [±9.1] years), with 52 percent being female. Subgroups included 120 individuals (38.7%) with CSF measures of soluble triggering receptor expressed on myeloid cells 2, 80 participants (25.8%) with CSF measures of chitinase-3-like protein 1, and 110 individuals (35.5%) with longitudinal cognitive measures. The study found that cognitively normal individuals with positive CSF Aβ42/Aβ40 and p-tau181 had higher HR than healthy controls and those with positive CSF Aβ42/Aβ40 but negative p-tau181. WM tracts with elevated NII-HR in individuals with positive CSF Aβ42/Aβ40 and p-tau181 were primarily located in the posterior brain regions while those with elevated NII-HR in individuals with positive CSF Aβ42/Aβ40 and p-tau181 connected the posterior and anterior brain regions. A significant negative correlation between NII-HR and CSF Aβ42/Aβ40 was found in individuals with positive CSF Aβ42/Aβ40. Baseline NII-HR correlated with baseline cognitive composite score and predicted longitudinal cognitive decline. Those findings suggest that WM neuroinflammation undergoes alterations before the onset of AD clinical symptoms and that it interacts with amyloidosis. This highlights the potential value of noninvasive monitoring of WM neuroinflammation in AD progression and treatment.

15 December 2023 in NeuroImage: Clinical
Verified
Journal Article
Open access
GCGengsheng Chen
Gengsheng Chen
NMNicole S. McKay
Nicole S. McKay
BGBrian A. Gordon
Brian A. Gordon
JLJingxia Liu
Jingxia Liu
NJNelly Joseph-Mathurin
Nelly Joseph-Mathurin
TBTammie Benzinger
Tammie Benzinger
The use of biomarkers for the early detection of Alzheimer's disease (AD) is crucial for developing potential therapeutic treatments. Positron Emission Tomography (PET) is a well-established tool used to detect β-amyloid (Aβ) plaques in the brain. Previous studies have shown that cross-sectional biomarkers can predict cognitive decline (Schindler et al.,2021). However, it is still unclear whether longitudinal Aβ-PET may have additional value for predicting time to cognitive impairment in AD. The current study aims to evaluate the ability of baseline- versus longitudinal rate of change in-11C-Pittsburgh compound B (PiB) Aβ-PET to predict cognitive decline. A cohort of 153 participants who previously underwent PiB-PET scans and comprehensive clinical assessments were used in this study. Our analyses revealed that baseline Aβ is significantly associated with the rate of change in cognitive composite scores, with cognition declining more rapidly when baseline PiB Aβ levels were higher. In contrast, no signification association was identified between the rate of change in PiB-PET Aβ and cognitive decline. Additionally, the ability of the rate of change in the PiB-PET measures to predict cognitive decline was significantly influenced by APOE ε4 carrier status. These results suggest that a single PiB-PET scan is sufficient to predict cognitive decline and that longitudinal measures of Aβ accumulation do not improve the prediction of cognitive decline once someone is amyloid positive.

17 July 2025 in Journal of Alzheimer’s Disease
Verified
Journal Article
Closed access
GCGengsheng Chen
Gengsheng Chen
NMNicole S McKay
Nicole S McKay
BGBrian A Gordon
Brian A Gordon
NJNelly Joseph-Mathurin
Nelly Joseph-Mathurin
JLJingxia Liu
Jingxia Liu
TBTammie Benzinger
Tammie Benzinger
Background: As we transition to disease-modifying treatment for Alzheimer's disease (AD), identifying individuals most at risk for future cognitive decline is crucial. Amyloid PET, cerebrospinal fluid and more recently blood-based biomarkers can identify the first stage of AD. However, changes detectable by PiB-PET may precede the onset of the dementia by 20–30 years. MRI is a widely available tool for detecting longitudinal changes in brain structure, such as cortical thickness and hippocampal volume and may provide additional insight into which patients are at greatest risk to develop cognitive decline. Objective: To determine how well the hippocampal volume and cortical thickness, without specific AD biomarkers, can predict cognitive decline. Methods: MRI data from 344 participants (cognitively unimpaired or mild cognitive impairment, age 50–86) were used to evaluate if changes in cortical thickness and hippocampal volume predict cognitive decline, measured by a global cognitive composite score. A random coefficient model was employed to calculate longitudinal changes in cortical thickness and hippocampal volume and assess their ability to predict cognitive decline. Results: Baseline cortical thickness as well as hippocampal volume predicted cognitive decline, regardless of baseline cognitive status. In individuals unimpaired at baseline, decreases in cortical thickness and hippocampal volume independently predicted cognitive decline. For participants with baseline mild impairment, decreases in hippocampal volume predicted further cognitive decline. Conclusions: These findings indicate that MRI could serve as an effective tool for identifying individuals at elevated risk of cognitive decline, a growing public health concern as global populations continue to age.

7 December 2020 in Alzheimer's & Dementia
Verified
Journal Article
Open access
PDF file
GCGengsheng Chen
Gengsheng Chen
NMNicole Sarah McKay
Nicole Sarah McKay
BGBrian A. Gordon
Brian A. Gordon
JLJingxia Liu
Jingxia Liu
ADAylin Dincer
Aylin Dincer
TBTammie Benzinger
Tammie Benzinger
Background: Using biomarkers for early detection of Alzheimer disease (AD) is crucial for developing potential treatments. It has been hypothesized that longitudinal change in cortical thickness and hippocampal volume could be used to predict cognitive decline in individuals with AD. Here, using longitudinal MRI data, we evaluated whether changes in cortical thickness and hippocampal volume predicted changes in cognition, as measured by a battery of standardized tests.Method: 152 Participants (aged: 45‐86) who were enrolled in studies at the Knight ADRC at Washington University were included. Data was obtained through OASIS (www.oasis‐brains.org). Participants were classified as having normal cognition or early symptomatic AD, and were followed for 1‐8 years. Hippocampal volume was extracted, and cortical thickness measures were derived as an average of a set of FreeSurfer cortical regions (Figure 1). A random coefficient model was used to calculate longitudinal change in these biomarkers, and to assess whether these measures predict cognitive decline. Additional correlations between longitudinal changes in cognition and changes in cortical thickness, and hippocampal volume, were calculated using Spearman correlations.Result: We found that longitudinal change in cortical thickness and hippocampal volume significantly predicted the rate of decline measured from a battery of standardized cognitive tasks (Figure 2). Furthermore, longitudinal changes in these structural biomarkers were strongly correlated with cognitive decline measured by the Logical Memory IIA‐Delayed (Figure 3).Conclusion: Longitudinal changes in cortical thickness and hippocampal volume significantly predict cognitive decline on neuropsychological tests that address cognitive domains that are typically impacted by AD. To evaluate brain atrophy in a manner that could easily be examined in a clinical context, we did not limit the study to participants with known amyloid biomarker status. It has been postulated that once therapeutic agents for AD become available, we will have difficulty providing large scale screening tests in populations at risk due to limited availability of PET centers. As MRI is widely available, longitudinal volumetric MRI may potentially be used in the future to screen patients as a first step in a workup and evaluation for participation in clinical trials or, once approved, evaluation for therapy.

1 March 2020 in IEICE Transactions on Information and Systems
Verified
Journal Article
Open access
PDF file
XZXinyu Zhu
Xinyu Zhu
JZJun Zhang
Jun Zhang
GCGengsheng Chen
Gengsheng Chen
Recent top-performing object detectors usually depend on a two-stage approach, which benefits from its region proposal and refining practice but suffers low detection speed. By contrast, one-stage approaches have the advantage of high efficiency while sacrifice their accuracies to some extent. In this paper, we propose a novel single-shot object detection network which inherits the merits of both. Motivated by the idea of semantic enrichment to the convolutional features within a typical deep detector, we propose two novel modules: 1) by modeling the semantic interactions between channels and the long-range dependencies between spatial positions, the self-attending module generates both channel and position attention, and enhance the original convolutional features in a self-guided manner; 2) leveraging the class-discriminative localization ability of classification-trained CNN, the semantic activating module learns a semantic meaningful convolutional response which augments low-level convolutional features with strong class-specific semantic information. The so called self-attending and semantic activating network (ASAN) achieves better accuracy than two-stage methods and is able to fulfil real-time processing. Comprehensive experiments on PASCAL VOC indicates that ASAN achieves state-of-the-art detection performance with high efficiency.

19 April 2026 in Research Square
Verified
Preprint
Open access
TBTammie Benzinger
Tammie Benzinger
SPSavannah Tiemann Powles
Savannah Tiemann Powles
DHDavid Hoagey
David Hoagey
SFShaney Flores
Shaney Flores
KFKarl Friedrichsen
Karl Friedrichsen
MBMatthew Brier
Matthew Brier
Neuroimmune signaling across the peripheral–vascular–glial axis is increasingly recognized as a driver of both age‑related brain vulnerability and the earliest stages of neurodegenerative disease, including Alzheimer disease. Evaluating this axis in vivo remains challenging due to limited neuroinflammatory imaging biomarkers. We utilized [11C]CS1P1 positron emission tomography (PET) to quantify sphingosine-1-phosphate receptor 1 (S1PR1) availability alongside plasma proteomics in 42 cognitively normal individuals (age 21-82). Through differential abundance analysis and structural equation modeling (SEM), we identified a multi-compartment neuroimmune cascade linking peripheral T-cell activation (CD40LG), vascular endothelial disruption (ICAM1/TEK), central S1PR1 upregulation, and reactive astrogliosis (GFAP). Mediation analysis estimated this S1PR1 axis accounts for 25.5% of the total effect of CD40LG on GFAP. This cascade appears coupled to the astrocytic immune response and is exacerbated by underlying amyloid-beta pathology. These findings suggest [11C]CS1P1 may serve as an in vivo tool for evaluating peripheral-to-central immune crosstalk.